Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass

Abelardo DeAnda, Steven E. Coutre, Marc R. Moon, Conrad M. Vial, Linda C. Griffin, Veronica S. Law, Masashi Komeda, Lawrence L K Leung, D. Craig Miller

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

Heparin is normally used for anticoagulation during cardiopulmonary bypass (CPB), but its use is contraindicated in patients with a history of heparin-induced thrombocytopenia, heparin-provoked thrombosis, or both. Heparin therapy can also be ineffective due to heparin resistance. A short-acting, oligonucleotide-based thrombin inhibitor (thrombin aptamer) may potentially serve as a substitute for heparin in these and other clinical situations. We tested a novel thrombin aptamer in a canine CPB pilot study to determine its anticoagulant efficacy, the resultant changes in coagulation variables, and the aptamer's clearance mechanisms and pharmacokinetics. Seven dogs were studied initially: Four received varied doses of the aptamer (to establish the pharmacokinetic profile) and 3 received heparin. Subsequently, 4 other dogs underwent CPB, receiving a constant infusion of the aptamer before CPB (to characterize the baseline coagulation status), with partial CPB and hemodilution, during 60 minutes of total CPB, and, finally, after a 2-hour recovery period. At a 0.5 mg · kg-1 · min-1 dose, the activated clotting time rose with aptamer infusion from 106 ± 12 seconds to 187 ± 8 seconds (± 1 standard deviation) (p = 0.014), increased further with hemodilution (to 259 ± 41 seconds; p = 0.017), and was even more prolonged during total CPB (> 1,500 seconds; p <0.001). This later increase in the activated clotting time paralleled a rise in the plasma concentration of the thrombin aptamer during total CPB, as determined by high-performance liquid chromatography. The calculated plasma aptamer elimination half-life increased from 1.9 minutes during baseline conditions to 7.7 minutes during total bypass, suggesting that the pulmonary vasculature plays a role in aptamer clearance. Importantly, the coagulation profile returned to normal levels within 5 minutes of halting aptamer infusion. There was no difference in platelet or fibrinogen consumption versus those of heparin. Postoperative bleeding (chest tube output) was minimal (95 to 150 mL over a 2-hour period), and serum chemistry profiles were normal. These preliminary pilot data indicate that this thrombin aptamer is both safe and, using conventional measures of anticoagulation, effective as an anticoagulant in this short-term canine CPB model, and that its pharmacokinetics are predictable. Furthermore, the pulmonary circulation appears to play a major role in the clearance of the aptamer.

Original languageEnglish (US)
Pages (from-to)344-350
Number of pages7
JournalThe Annals of Thoracic Surgery
Volume58
Issue number2
StatePublished - Aug 1994
Externally publishedYes

Fingerprint

Cardiopulmonary Bypass
Thrombin
Heparin
Hemodilution
Pharmacokinetics
Anticoagulants
Canidae
Dogs
Chest Tubes
Pulmonary Circulation
Oligonucleotides
Thrombocytopenia
Fibrinogen
Half-Life
Thrombosis
Blood Platelets
High Pressure Liquid Chromatography
Hemorrhage
Lung
thrombin aptamer

ASJC Scopus subject areas

  • Surgery
  • Cardiology and Cardiovascular Medicine

Cite this

DeAnda, A., Coutre, S. E., Moon, M. R., Vial, C. M., Griffin, L. C., Law, V. S., ... Miller, D. C. (1994). Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass. The Annals of Thoracic Surgery, 58(2), 344-350.

Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass. / DeAnda, Abelardo; Coutre, Steven E.; Moon, Marc R.; Vial, Conrad M.; Griffin, Linda C.; Law, Veronica S.; Komeda, Masashi; Leung, Lawrence L K; Miller, D. Craig.

In: The Annals of Thoracic Surgery, Vol. 58, No. 2, 08.1994, p. 344-350.

Research output: Contribution to journalArticle

DeAnda, A, Coutre, SE, Moon, MR, Vial, CM, Griffin, LC, Law, VS, Komeda, M, Leung, LLK & Miller, DC 1994, 'Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass', The Annals of Thoracic Surgery, vol. 58, no. 2, pp. 344-350.
DeAnda, Abelardo ; Coutre, Steven E. ; Moon, Marc R. ; Vial, Conrad M. ; Griffin, Linda C. ; Law, Veronica S. ; Komeda, Masashi ; Leung, Lawrence L K ; Miller, D. Craig. / Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass. In: The Annals of Thoracic Surgery. 1994 ; Vol. 58, No. 2. pp. 344-350.
@article{1ba92646a63c4563a562928735fea12b,
title = "Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass",
abstract = "Heparin is normally used for anticoagulation during cardiopulmonary bypass (CPB), but its use is contraindicated in patients with a history of heparin-induced thrombocytopenia, heparin-provoked thrombosis, or both. Heparin therapy can also be ineffective due to heparin resistance. A short-acting, oligonucleotide-based thrombin inhibitor (thrombin aptamer) may potentially serve as a substitute for heparin in these and other clinical situations. We tested a novel thrombin aptamer in a canine CPB pilot study to determine its anticoagulant efficacy, the resultant changes in coagulation variables, and the aptamer's clearance mechanisms and pharmacokinetics. Seven dogs were studied initially: Four received varied doses of the aptamer (to establish the pharmacokinetic profile) and 3 received heparin. Subsequently, 4 other dogs underwent CPB, receiving a constant infusion of the aptamer before CPB (to characterize the baseline coagulation status), with partial CPB and hemodilution, during 60 minutes of total CPB, and, finally, after a 2-hour recovery period. At a 0.5 mg · kg-1 · min-1 dose, the activated clotting time rose with aptamer infusion from 106 ± 12 seconds to 187 ± 8 seconds (± 1 standard deviation) (p = 0.014), increased further with hemodilution (to 259 ± 41 seconds; p = 0.017), and was even more prolonged during total CPB (> 1,500 seconds; p <0.001). This later increase in the activated clotting time paralleled a rise in the plasma concentration of the thrombin aptamer during total CPB, as determined by high-performance liquid chromatography. The calculated plasma aptamer elimination half-life increased from 1.9 minutes during baseline conditions to 7.7 minutes during total bypass, suggesting that the pulmonary vasculature plays a role in aptamer clearance. Importantly, the coagulation profile returned to normal levels within 5 minutes of halting aptamer infusion. There was no difference in platelet or fibrinogen consumption versus those of heparin. Postoperative bleeding (chest tube output) was minimal (95 to 150 mL over a 2-hour period), and serum chemistry profiles were normal. These preliminary pilot data indicate that this thrombin aptamer is both safe and, using conventional measures of anticoagulation, effective as an anticoagulant in this short-term canine CPB model, and that its pharmacokinetics are predictable. Furthermore, the pulmonary circulation appears to play a major role in the clearance of the aptamer.",
author = "Abelardo DeAnda and Coutre, {Steven E.} and Moon, {Marc R.} and Vial, {Conrad M.} and Griffin, {Linda C.} and Law, {Veronica S.} and Masashi Komeda and Leung, {Lawrence L K} and Miller, {D. Craig}",
year = "1994",
month = "8",
language = "English (US)",
volume = "58",
pages = "344--350",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "2",

}

TY - JOUR

T1 - Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass

AU - DeAnda, Abelardo

AU - Coutre, Steven E.

AU - Moon, Marc R.

AU - Vial, Conrad M.

AU - Griffin, Linda C.

AU - Law, Veronica S.

AU - Komeda, Masashi

AU - Leung, Lawrence L K

AU - Miller, D. Craig

PY - 1994/8

Y1 - 1994/8

N2 - Heparin is normally used for anticoagulation during cardiopulmonary bypass (CPB), but its use is contraindicated in patients with a history of heparin-induced thrombocytopenia, heparin-provoked thrombosis, or both. Heparin therapy can also be ineffective due to heparin resistance. A short-acting, oligonucleotide-based thrombin inhibitor (thrombin aptamer) may potentially serve as a substitute for heparin in these and other clinical situations. We tested a novel thrombin aptamer in a canine CPB pilot study to determine its anticoagulant efficacy, the resultant changes in coagulation variables, and the aptamer's clearance mechanisms and pharmacokinetics. Seven dogs were studied initially: Four received varied doses of the aptamer (to establish the pharmacokinetic profile) and 3 received heparin. Subsequently, 4 other dogs underwent CPB, receiving a constant infusion of the aptamer before CPB (to characterize the baseline coagulation status), with partial CPB and hemodilution, during 60 minutes of total CPB, and, finally, after a 2-hour recovery period. At a 0.5 mg · kg-1 · min-1 dose, the activated clotting time rose with aptamer infusion from 106 ± 12 seconds to 187 ± 8 seconds (± 1 standard deviation) (p = 0.014), increased further with hemodilution (to 259 ± 41 seconds; p = 0.017), and was even more prolonged during total CPB (> 1,500 seconds; p <0.001). This later increase in the activated clotting time paralleled a rise in the plasma concentration of the thrombin aptamer during total CPB, as determined by high-performance liquid chromatography. The calculated plasma aptamer elimination half-life increased from 1.9 minutes during baseline conditions to 7.7 minutes during total bypass, suggesting that the pulmonary vasculature plays a role in aptamer clearance. Importantly, the coagulation profile returned to normal levels within 5 minutes of halting aptamer infusion. There was no difference in platelet or fibrinogen consumption versus those of heparin. Postoperative bleeding (chest tube output) was minimal (95 to 150 mL over a 2-hour period), and serum chemistry profiles were normal. These preliminary pilot data indicate that this thrombin aptamer is both safe and, using conventional measures of anticoagulation, effective as an anticoagulant in this short-term canine CPB model, and that its pharmacokinetics are predictable. Furthermore, the pulmonary circulation appears to play a major role in the clearance of the aptamer.

AB - Heparin is normally used for anticoagulation during cardiopulmonary bypass (CPB), but its use is contraindicated in patients with a history of heparin-induced thrombocytopenia, heparin-provoked thrombosis, or both. Heparin therapy can also be ineffective due to heparin resistance. A short-acting, oligonucleotide-based thrombin inhibitor (thrombin aptamer) may potentially serve as a substitute for heparin in these and other clinical situations. We tested a novel thrombin aptamer in a canine CPB pilot study to determine its anticoagulant efficacy, the resultant changes in coagulation variables, and the aptamer's clearance mechanisms and pharmacokinetics. Seven dogs were studied initially: Four received varied doses of the aptamer (to establish the pharmacokinetic profile) and 3 received heparin. Subsequently, 4 other dogs underwent CPB, receiving a constant infusion of the aptamer before CPB (to characterize the baseline coagulation status), with partial CPB and hemodilution, during 60 minutes of total CPB, and, finally, after a 2-hour recovery period. At a 0.5 mg · kg-1 · min-1 dose, the activated clotting time rose with aptamer infusion from 106 ± 12 seconds to 187 ± 8 seconds (± 1 standard deviation) (p = 0.014), increased further with hemodilution (to 259 ± 41 seconds; p = 0.017), and was even more prolonged during total CPB (> 1,500 seconds; p <0.001). This later increase in the activated clotting time paralleled a rise in the plasma concentration of the thrombin aptamer during total CPB, as determined by high-performance liquid chromatography. The calculated plasma aptamer elimination half-life increased from 1.9 minutes during baseline conditions to 7.7 minutes during total bypass, suggesting that the pulmonary vasculature plays a role in aptamer clearance. Importantly, the coagulation profile returned to normal levels within 5 minutes of halting aptamer infusion. There was no difference in platelet or fibrinogen consumption versus those of heparin. Postoperative bleeding (chest tube output) was minimal (95 to 150 mL over a 2-hour period), and serum chemistry profiles were normal. These preliminary pilot data indicate that this thrombin aptamer is both safe and, using conventional measures of anticoagulation, effective as an anticoagulant in this short-term canine CPB model, and that its pharmacokinetics are predictable. Furthermore, the pulmonary circulation appears to play a major role in the clearance of the aptamer.

UR - http://www.scopus.com/inward/record.url?scp=0027956461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027956461&partnerID=8YFLogxK

M3 - Article

VL - 58

SP - 344

EP - 350

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 2

ER -